Medplum vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 38)
Medplum logo

Medplum

EmergingHealthcare

General

"Firebase for healthcare" open-source FHIR EHR API infrastructure; YC S22 $550K with $1.2M revenue serving thousands of health tech developers competing with Google Cloud Healthcare API for HIPAA-compliant infrastructure.

AI VisibilityBeta
Overall Score
D38
Category Rank
#464 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
32
Gemini
36

About

Medplum is a San Francisco-based open-source EHR and healthcare API infrastructure company — often described as "Firebase for healthcare" — providing FHIR-compliant API infrastructure, clinical data management, and workflow tools that healthcare developers use to build EMR-adjacent applications, care management platforms, and health tech products without building from scratch the compliance, data modeling, and interoperability layers that healthcare applications require. Founded in 2021 and backed by Y Combinator (S22) with $550,000 raised, Medplum achieved $1.2 million in revenue in 2024 serving thousands of developers globally building on the open-source platform.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

38
Overall Score
93
#464
Category Rank
#1
81
AI Consensus
80
stable
Trend
stable
39
ChatGPT
94
32
Perplexity
89
36
Gemini
94
40
Claude
92
38
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.